Promis Neurosciences (NASDAQ:PMN) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Promis Neurosciences (NASDAQ:PMN) announced its earnings results on Wednesday. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09), Zacks reports.

Promis Neurosciences Stock Down 0.2%

PMN traded down $0.00 on Friday, hitting $0.39. 492,016 shares of the company traded hands, compared to its average volume of 2,441,040. Promis Neurosciences has a 12-month low of $0.36 and a 12-month high of $1.59. The company has a 50 day moving average of $0.44 and a 200-day moving average of $0.52. The stock has a market capitalization of $20.96 million, a PE ratio of -0.51 and a beta of -0.22.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Leede Financial upgraded shares of Promis Neurosciences to a “moderate buy” rating in a report on Monday, July 21st. Wall Street Zen lowered Promis Neurosciences to a “strong sell” rating in a research note on Saturday, October 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Promis Neurosciences in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.33.

Promis Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.